T-20 (Enfuvirtide, Fuzeon): News
- Update to Fuzeon (Enfuvirtide) Label Regarding Incidence of Bacterial Pneumonia (May 2, 2011)
From U.S. Food and Drug Administration
- Important Information About Alcohol Prep Pads Packaged With Fuzeon and Certain Other Injection Products (February 8, 2011)
From U.S. Food and Drug Administration
- Cautionary Recall of Swabs Used For Fuzeon and Pegasys Announced (February 2011)
To read PDF, click here.
In Project Inform Perspective, from Project Inform
- Companies Abandon Needle-Free Injection System for Fuzeon (October 4, 2007)
From Project Inform
- Important Changes to Fuzeon Product Labeling (January 31, 2007)
From U.S. Food and Drug Administration
- Raleigh News & Observer Examines Efforts to Increase Sales of Fuzeon in North America (November 2, 2005)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Chinese Company Is Developing New Drug Modeled After T-20; Aiming for 2006 Release (July 11, 2005)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Fuzeon Accelerated Simultaneous Access Program (Fuzeon ASAP) (September 2004)
A new program provides "immediate" supplies of T-20 to patients who are prescribed the drug together with another investigational drug.
From Roche Laboratories, Inc. and Trimeris, Inc.
- Fuzeon Fizzles: Bungled T-20 Launch Claims Its First Casualties, as Losses Spread (March 2004)
In TAGline, from Treatment Action Group
- Access Information for T-20 (Fuzeon), Atazanavir (Reyataz) and FTC (Emtriva) (October 2003)
How to get information about receiving these new HIV medications through ADAPs and Patient Assistance Programs.
To read PDF, click here.
In Project Inform Perspective, from Project Inform
- Antiretroviral Drug Fuzeon Sales Slower Than Expected; High Cost, Injection Delivery Method Cited (September 16, 2003)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- AIDS Drug's Promise and Price Collide (August 29, 2003)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Denver Post Examines High Cost, Limited Accessibility of Roche's Antiretroviral Drug Fuzeon (August 25, 2003)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Roche Able to Produce More Fuzeon Than Expected (July 15, 2003)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Washington, D.C. Delays Approving City's ADAP Coverage for T-20 (July 2, 2003)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Most U.S. Insurers Will Cover Cost of T-20 (May 15, 2003)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- ConFuzeon Reigns (April 2003)
More details of Roche's T-20 distribution plan.
In GMHC Treatment Issues, from Gay Men's Health Crisis
- U.S. Price for AIDS Drug: $20,000 (March 24, 2003)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Roche/Trimeris to Help Patients Get Fuzeon (March 17, 2003)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Activists Protest Cost of New AIDS Drug (March 17, 2003)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- T-20: Most Expensive AIDS Drug Ever at $25,000 Per Year? (March 14, 2003)
In AIDS Treatment News, from AIDS Treatment News
|
Advertisement
|
Email
Glossary
